GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
52.50
+0.61 (1.18%)
At close: Jun 26, 2026, 4:00 PM EDT
52.51
+0.01 (0.03%)
After-hours: Jun 26, 2026, 7:29 PM EDT
GSK Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or -2.61% compared to the previous year.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
$647,583
Profits / Employee
$115,154
Market Cap
104.43B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
| Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
| Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
| Dec 31, 2017 | 98,462 | -838 | -0.84% |
| Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
| Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
| Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
| Dec 31, 2013 | 99,451 | -37 | -0.04% |
| Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
| Dec 31, 2011 | 97,389 | 928 | 0.96% |
| Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
| Dec 31, 2009 | 99,913 | 910 | 0.92% |
| Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
| Dec 31, 2007 | 103,483 | 788 | 0.77% |
| Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
| Dec 31, 2005 | 100,728 | 709 | 0.71% |
| Dec 31, 2004 | 100,019 | -900 | -0.89% |
| Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
| Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
| Dec 31, 2001 | 107,470 | -47 | -0.04% |
| Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
| Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
| Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Pfizer | 75,000 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| AbbVie | 57,000 |
| Bristol-Myers Squibb Company | 32,500 |
GSK News
- 3 days ago - GSK Initiates Tender Offer for Nuvalent Shares - GuruFocus
- 4 days ago - GSK announces commencement of tender offer to acquire Nuvalent - TheFly
- 10 days ago - Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up - Nasdaq
- 10 days ago - Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - Business Wire
- 10 days ago - GSK Secures FDA Approval for Utebzi, First Oral Carbapenem for UTIs - GuruFocus
- 10 days ago - Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs) - GlobeNewsWire
- 10 days ago - GSK Gains FDA Approval for New Oral Antibiotic Utebzi - GuruFocus
- 11 days ago - GSK, Spero Therapeutics announce FDA approval of Utebzi - TheFly